Supplementary Figure 1:
False positive rate threshold analysis. As part of filtering for novel QT-DDIs in FAERS we only kept predictions below a certain false positive rate (FPR) threshold. To determine this threshold, at each FPR from 1-100% (1-10% FPR shown) we first calculated the mean false discovery rate (FDR) for the true CredibleMeds evaluation labels (i.e. any pair containing a known CredibleMeds drug is labeled as a positive example) after randomly sampling with replacement from the set of drug pairs over 1000 iterations (blue). We also calculated the FDR for 1000 iterations of random shuffling of these labels (orange). We next fit a sigmoid function to the bootstrapped mean FDRs representing the expected increase in FDR as the FPR threshold increases. Because a number of the "false positives" as evaluated with the CredibleMeds validation represent previously unknown QT-DDIs, we selected 4% FPR as it was the smallest false positive rate whose mean FDR was above the best fit line while also ensuring a sufficient number of predictions for retrospective validation in the electronic health records (white text on blue bars). This FPR threshold corresponds to a classifier probability of 33.26%. 
Supplementary Figure 4: Scatter plot comparing median QTc intervals (in milliseconds) on single drug (x-axis) and combination therapy (y-axis). (A) Results for males. (B)
Results for females. In both panels a minimum of 50 patients on the drug pair was necessary for inclusion in the plot. A red circle indicates a drug pair that had significantly increased QTc compared to the single drug control in the EHR analysis. A green circle indicates a drug pair that had significantly decreased QTc compared to the single drug control. The best fit line is indicated in dashed gray.
Supplementary Figure 5
: DIPULSE generates significantly more true predictions than would be expected by chance alone. DIPULSE generated 889 putative DDIs for EHR analysis, of which 49 results (drug pair and a given sex) were found to be significant (red line). Over 1000 iterations, we randomly selected 889 pairs from the frequency table for drug pairs such that one of the drugs in the pair was a "control" drug (i.e. the drug with the greatest QTc interval alone from the latent evidence pair). We also matched the number of cases (patients prescribed the drug pair) in the random pairs to the case group sizes in the latent evidence pairs. For each iteration we counted the number of significant results to build an empirical distribution (blue). DIPULSE significantly enriched for drug interactions that actually prolong the QT interval (P = 0.01). 
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